Literature DB >> 10883725

Nithsdale schizophrenia surveys 21: a longitudinal study of National Adult Reading Test stability.

G Morrison1, V Sharkey, J Allardyce, R C Kelly, R G McCreadie.   

Abstract

BACKGROUND: The stability of the National Adult Reading Test (NART) as a measure of pre-morbid intelligence in schizophrenia has not yet been satisfactorily established despite the widespread use of the NART in schizophrenia research.
METHOD: We examined NART stability in a diverse group of 45 schizophrenic patients in a prospective longitudinal study over 6.5-7.5 years.
RESULTS: The results showed that NART performance does not decline significantly with increasing duration of schizophrenic illness and that test-retest reliability, even over 6.5-7.5 years, is extremely high. DISCUSSION: Our results provide the necessary evidence that the NART can be used as a stable measure of pre-morbid intelligence in schizophrenia.

Entities:  

Mesh:

Year:  2000        PMID: 10883725     DOI: 10.1017/s0033291799001920

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  9 in total

1.  Reading Ability as an Estimator of Premorbid Intelligence: Does It Remain Stable Among Ethnically Diverse HIV+ Adults?

Authors:  James P Olsen; Robert P Fellows; Monica Rivera-Mindt; Susan Morgello; Desiree A Byrd
Journal:  Clin Neuropsychol       Date:  2015-12-21       Impact factor: 3.535

2.  Neuropsychological functioning in early and chronic stages of schizophrenia and psychotic bipolar disorder.

Authors:  Margo W Menkes; Kristan Armstrong; Jennifer Urbano Blackford; Stephan Heckers; Neil D Woodward
Journal:  Schizophr Res       Date:  2018-10-26       Impact factor: 4.939

3.  The acceptability and feasibility of a novel virtual reality based social skills training game for schizophrenia: Preliminary findings.

Authors:  Laura H Adery; Megan Ichinose; Lénie J Torregrossa; Joshua Wade; Heathman Nichols; Esube Bekele; Dayi Bian; Alena Gizdic; Eric Granholm; Nilanjan Sarkar; Sohee Park
Journal:  Psychiatry Res       Date:  2018-10-09       Impact factor: 3.222

Review 4.  A Brief Assessment of Intelligence Decline in Schizophrenia As Represented by the Difference between Current and Premorbid Intellectual Quotient.

Authors:  Kazutaka Ohi; Chika Sumiyoshi; Haruo Fujino; Yuka Yasuda; Hidenaga Yamamori; Michiko Fujimoto; Tomiki Sumiyoshi; Ryota Hashimoto
Journal:  Front Psychiatry       Date:  2017-12-22       Impact factor: 4.157

5.  Association between lower estimated premorbid intelligence quotient and smoking behavior in patients with schizophrenia.

Authors:  Shinsuke Hidese; Junko Matsuo; Ikki Ishida; Moeko Hiraishi; Toshiya Teraishi; Miho Ota; Kotaro Hattori; Hiroshi Kunugi
Journal:  Schizophr Res Cogn       Date:  2018-10-09

6.  Stability of Estimated Premorbid Cognitive Ability over Time after Minor Stroke and Its Relationship with Post-Stroke Cognitive Ability.

Authors:  Caroline A McHutchison; Francesca M Chappell; Stephen Makin; Kirsten Shuler; Joanna M Wardlaw; Vera Cvoro
Journal:  Brain Sci       Date:  2019-05-22

7.  Emotional prosody modulates attention in schizophrenia patients with hallucinations.

Authors:  L Alba-Ferrara; G A de Erausquin; M Hirnstein; S Weis; M Hausmann
Journal:  Front Hum Neurosci       Date:  2013-03-04       Impact factor: 3.169

8.  IQ trajectory, cognitive reserve, and clinical outcome following a first episode of psychosis: a 3-year longitudinal study.

Authors:  Verity C Leeson; Pranev Sharma; Masuma Harrison; Maria A Ron; Thomas R E Barnes; Eileen M Joyce
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

9.  Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis.

Authors:  V A Morgan; J J McGrath; A Jablensky; J C Badcock; A Waterreus; R Bush; V Carr; D Castle; M Cohen; C Galletly; C Harvey; B Hocking; P McGorry; A L Neil; S Saw; S Shah; H J Stain; A Mackinnon
Journal:  Psychol Med       Date:  2013-12-23       Impact factor: 7.723

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.